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Abstract. 
 
Insulin-like growth factor (IGF) II is overex-
pressed in many human cancers and is reactivated by, 
and crucial for viral oncogene (SV40 T antigen, [TAg])–
induced tumorigenesis in several tumor models. Using a 
double transgenic murine hepatic tumor model, we 
demonstrate that tissue inhibitor of metalloproteinase 1 
(TIMP-1) blocks liver hyperplasia during tumor devel-
opment, despite TAg-mediated reactivation of IGF-II. 
Because the activity of IGFs is controlled by IGF-bind-
ing proteins (IGFBPs), we investigated whether TIMP-1 
overexpression altered the IGFBP status in the trans-
genic liver. Ligand blotting showed that IGFBP-3 pro-
tein levels were increased in TIMP-1–overexpressing 
double transgenic littermates, whereas IGFBP-3 
mRNA levels were not different, suggesting that TIMP-1 
affects IGFBP-3 at a posttranscriptional level. IGFBP-3 
proteolysis assays demonstrated that IGFBP-3 degra-
dation was lower in TIMP-1–overexpressing livers, and 
zymography showed that matrix metalloproteinases 
(MMPs) were present in the liver homogenates and 
were capable of degrading IGFBP-3. As a consequence 
of reduced IGFBP-3 proteolysis and elevated IGFBP-3 
protein levels, dissociable IGF-II levels were signiﬁ-
cantly lower in TIMP-1–overexpressing animals. This 
decrease in bioavailable IGF-II ultimately resulted in 
diminished IGF-I receptor signaling in vivo as evi-
denced by diminished receptor kinase activity and de-
creased tyrosine phosphorylation of the IGF-I receptor 
downstream effectors, insulin receptor substrate 1 
(IRS-1), extracellular signal regulatory kinase (Erk)-1, 
and Erk-2. Together, these results provide evidence 
that TIMP-1 inhibits liver hyperplasia, an early event in 
TAg-mediated tumorigenesis, by reducing the activity 
of the tumor-inducing mitogen, IGF-II. These data im-
plicate the control of MMP-mediated degradation of 
IGFBPs as a novel therapy for controlling IGF bio-
availability in cancer.
Key words: TIMP-1 • insulin-like growth factor II • 
signal transduction • extracellular proteolysis • tumor 
suppression
 
E
 
XTRACELLULAR
 
 matrix (ECM)
 
1
 
 serves as the imme-
diate microenvironment for interactions with the
cell surface, besides providing the structural sup-
port for all tissues. The ECM is not static. Rather, it is dy-
namic in nature with a continuous turnover of its protein
constituents and growth factor pools. A major determi-
nant of ECM turnover and integrity is the extracellular
proteolytic balance between secreted matrix metallopro-
teinases (MMPs) and their biological inhibitors (TIMPs)
(for reviews see Matrisian, 1992; Denhardt et al., 1993;
Mignatti and Rifkin, 1993). The function of extracellular
proteolysis extends beyond ECM degradation to the pro-
cessing of cell surface receptors and ligands and release of
protein-bound growth factors (for review see Werb, 1997).
Therefore, it is conceivable that extracellular proteolytic
activity within the cellular microenvironment can directly
impact cell proliferation. Despite transgenic studies show-
ing that cellular proliferation is altered by ectopic ex-
pression of MMPs or TIMPs (Sympson et al., 1994;
D’Armiento et al., 1995; Witty et al., 1995; Martin et al.,
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1999), the question of whether TIMP/MMP-mediated pro-
teolysis affects growth factor bioavailability in vivo to reg-
ulate cell proliferation has not been investigated.
Insulin-like growth factors (IGFs) are important mito-
gens in many normal and pathological systems. IGFs are
essential for normal embryonic and postnatal growth
(Murphy et al., 1987; Han et al., 1988), and their overex-
pression is frequently observed in hyperproliferative states
that occur in human cancers of the prostate, breast, and
liver (Osborne et al., 1989; D’Errico et al., 1994; Tennant
et al., 1996). Moreover, IGF overexpression in cancer is
associated with poor patient prognosis (Chan et al., 1998;
Hankinson et al., 1998). IGFs are considered survival fac-
tors, and depending on cell type and situation, demon-
strate either a direct proliferative effect (Schoenle et al.,
1985; Osborne et al., 1989) or an antiapoptotic effect
(Bozyczko-Coyne et al., 1993; Resnicoff et al., 1995). In
accordance with their diverse biological activities, there is
a complex regulation of IGF bioactivity. In the extracellu-
lar compartment, IGF activity is controlled by six known
high affinity IGF-binding proteins (IGFBPs) which bind
the IGFs with equal or higher affinity than the type I IGF
receptor (IGF-IR; McCusker et al., 1991; Shimisaki and
Ling, 1991). The molar excess of IGFBPs, along with their
higher affinity, leads to effective sequestration of IGFs by
IGFBPs, resulting in little or no free IGFs in most biologi-
cal systems. Nevertheless, proteolytic cleavage of IGFBPs
by aspartic, serine, and metalloproteinases (Cohen et al.,
1992; Conover et al., 1994; Fowlkes et al., 1994a) has been
shown to release IGFs in vitro, because IGFBP fragments
demonstrate significantly lower affinities for IGFs than
the intact IGFBPs (Gargosky et al., 1992; Lassarre and
Binoux, 1994; Lassarre et al., 1994). Once released from
IGFBPs, both IGF-I and IGF-II exert their mitogenic ef-
fects through IGF-IR, a protein tyrosine kinase receptor
(Osborne et al., 1989; Rubin and Baserga, 1995; Fowlkes,
1997). Therefore, the mitogenic activity of IGFs may be
regulated at the level of IGF expression, IGFBP seques-
tration, proteinase-mediated IGFBP proteolysis to release
free IGF, or IGF-IR signaling.
We explored whether the TIMP/MMP balance alters
cell proliferation by regulating IGF-II bioactivity in vivo
by using a double transgenic mouse model that carries
the tumor-inducing viral oncoprotein, (SV40 T antigen,
[TAg]) and the tumor-suppressing TIMP-1 transgene (Mar-
tin et al., 1996). In this model, we have already shown that
hepatic TIMP-1 overexpression inhibits TAg-induced he-
patocyte hyperplasia and liver tumorigenesis (Martin et al.,
1996, 1999). Since TAg transformation is unsuccessful fol-
lowing IGF-IR ablation (Sell et al., 1993), and TAg-
induced pancreatic tumorigenesis is substantially reduced
by IGF-II ablation (Christofori et al., 1994), the IGF path-
way appears to be crucial for TAg oncoprotein transfor-
mation. Our double transgenic model presented an ideal
opportunity to investigate the potential effects of trans-
genic TIMP-1 overexpression on IGF bioactivity. Here,
we demonstrate that despite IGF-II reactivation during
TAg-induced tumorigenesis, transgenic TIMP-1 overex-
pression attenuates IGF-II bioactivity. This is due to the
inhibition of MMP-mediated IGFBP-3 proteolysis leading to
elevated IGFBP-3 levels and reduced dissociable IGF-II
levels in hepatic tissues. Reduced IGF-II bioactivity in vivo
was confirmed by decreased signaling through the IGF-IR
signal transduction pathway. To our knowledge, this is the
first in vivo example of the modulation of growth factor
bioactivity by the regulation of extracellular proteolysis.
 
Materials and Methods
 
Transgenic Mice
 
Transgenic mice expressing the TIMP-1 (Ts
 
1
 
) or TAg (TAg
 
1
 
) transgenes
in liver were generated and bred as described previously (Martin et al.,
1996). Single transgenics were crossed to generate four categories of litter-
mates designated as wild-type controls (TAg
 
2
 
/Ts
 
2
 
), TIMP-1 controls
(Ts
 
1
 
), TAg controls (TAg
 
1
 
), and double transgenic TIMP-1–overexpress-
ing (TAg
 
1
 
/Ts
 
1
 
) mice. Female littermates were killed at specified ages, and
the liver tissue was processed and embedded or flash frozen for analyses.
 
Immunoprecipitation and Western Blotting
 
Liver tissue was homogenized in lysis buffer (20 mM Tris-HCl, pH 7.4,
1.0% NP-40, 150 mM NaCl, 0.5 M PMSF, 1 mM EDTA, 10 
 
m
 
g/ml pepsta-
tin, 10 
 
m
 
g/ml leupeptin) at 4
 
8
 
C. Samples were centrifuged for 10 min at
16,000 
 
g
 
, the supernatants collected, and the protein content determined
by the Bradford assay. Aliquots containing 2.5 mg of protein were ad-
justed to a volume of 500 
 
m
 
l. TAg was immunoprecipitated by adding 0.5
 
m
 
g/ml of anti-SV40 large T small t antibody (clone PAb 108; PharMingen)
and 50 
 
m
 
l of Gamma Bind Plus Sepharose (Amersham Pharmacia Bio-
tech), and rocking for 2 h at 4
 
8
 
C. Immunoprecipitates were collected by
centrifugation in a refrigerated Eppendorf centrifuge and washed three
times with NET/gel buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1%
NP-40, 1 mM EDTA, 0.25% gelatin, 0.02% sodium azide). The samples
were subjected to 10% SDS-PAGE and electroblotted to Hybond N ny-
lon membrane (Amersham Pharmacia Biotech). The membranes were se-
quentially probed with primary antibodies PAb 108, anti-p53 (clone PAb
421; obtained from Dr. S. Benchimol, Ontario Cancer Institute), and anti-
RB (clone G3-245; PharMingen), followed by hybridization with peroxi-
dase-conjugated anti–mouse IgG antibodies and ECL chemiluminescence
(Amersham Pharmacia Biotech).
 
Northern Blotting
 
Total RNA isolated from individual liver tissue samples (20 
 
m
 
g) was elec-
trophoresed in formaldehyde agarose gels, subjected to Northern blotting
and sequential hybridizations with [
 
a
 
-
 
32
 
P]dCTP-labeled and random
primed cDNA probes for murine IGF-II (cDNA obtained from Dr. G.
Bell, University of Chicago, Chicago, IL), rat IGFBP-3 (cDNA, obtained
from Dr. A. Herington, Queensland University of Technology, Brisbane,
Australia), 18S ribosomal RNA, and glyceraldehyde 6-phosphate dehy-
drogenase (GAPDH) were performed. The latter two probes were used
to control for equal loading and transfer of samples.
 
Immunohistochemistry and In Situ Hybridization
 
Paraffin sections of formalin-fixed liver tissue were generated as described
previously (Martin et al., 1999). Clone PAb 108, biotinylated goat anti–
mouse IgG, and streptavidin-peroxidase conjugate (Zymed) were used for
TAg immunohistochemistry, and peroxidase-conjugated anti–proliferat-
ing cell nuclear antigen (PCNA) antibodies (Dako) were used to detect
proliferating cells. The detection of bound antibody was carried out using
diaminobenzidine (Kirkegaard & Perry), which forms a reddish-brown
pigment at sites of peroxidase activity. Digoxygenin-labeled (Boehringer
Mannheim) IGF-II riboprobes were synthesized using the rat IGF-II
cDNA, which was cloned in Bluescript KS. In situ hybridization was per-
formed as described previously (Martin et al., 1999). Specific signal ap-
pears as purple pigment.
 
Ligand Blotting
 
Liver samples were homogenized as for Western blotting. Equivalent
amounts of protein from each sample (40 
 
m
 
g) were subjected to 10% SDS-
PAGE followed by electroblotting to Hybond N. Membranes were
blocked by incubating for 1 h in blocking buffer (10% BSA in TBS, 0.01 M
Tris-HCl, pH 7.5, 0.15 M NaCl) followed by overnight hybridization with
50,000 cpm/ml 
 
125
 
I–IGF-II (Amersham Pharmacia Biotech) in blocking 
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buffer. Membranes were washed three times for 15 min with TBS, air
dried, then subjected to autoradiography.
 
IGFBP-3 Substrate Zymography
 
Liver samples were prepared as for Western blotting. Protein from each
sample (40 
 
m
 
g) was subjected to SDS-PAGE in a 10% polyacrylamide gel
containing 1.0 
 
m
 
g/ml recombinant human IGFBP-3 (kindly provided by
Dr. C. Maack, Celtrix Pharmaceuticals, Santa Clara, CA). Following elec-
trophoresis, gels were washed for 30 min with 2.5% Triton X-100. Gels
were equilibrated with transfer buffer (50 mM Tris-HCl, pH 8.0, 5 mM
CaCl
 
2
 
), then the proteins were subjected to capillary transfer onto PVDF
membranes as described previously (Fowlkes et al., 1997). The transfer
was performed either in the absence or presence of 10.0 
 
m
 
g/ml recombi-
nant human TIMP-1 (kindly provided by Dr. H. Nagase, University of
Kansas, Kansas City, KS). Transfers took place overnight at 37
 
8
 
C. Under
these conditions, only proteolytic fragments of IGFBP-3 transfer from the
substrate-gel to the membrane. Intact IGFBP-3 (30 kD) impregnated in
the polyacrylamide matrix remains in the gel (Fowlkes et al., 1997). Fol-
lowing transfer, the PVDF membrane was probed with polyclonal anti-
body against IGFBP-3 (Fowlkes et al., 1997).
 
IGFBP-3 Degradation Assay
 
Liver tissue was homogenized as for Western blotting, except that NP-40
and proteinase inhibitors were not added. 50 
 
m
 
g of protein from each sam-
ple was brought up to a volume of 28 
 
m
 
l with homogenization buffer con-
taining 50 
 
m
 
M CaCl
 
2
 
. 
 
125
 
I–IGFBP-3 (50,000 cpm/ml; Diagnostic Systems
Laboratories) was added, and the samples were incubated for 5 h at 37
 
8
 
C,
followed by SDS-PAGE, electroblotting, and autoradiography (Daven-
port et al., 1991).
 
Affinity Chromatography
 
Liver protein homogenates were prepared as above. Total levels of IGF-II
were quantified according to a published protocol (De Leon and As-
merom, 1997). In brief, 10 
 
m
 
l from each sample was dot blotted onto nitro-
cellulose in triplicate. The membrane was incubated in blocking buffer
and then with mAb against IGF-II. The IGF-II concentrations were deter-
mined from a standard curve generated with known quantities of purified
recombinant IGF-II (kindly provided by Eli Lilly and Co.). To assess the
relative levels of dissociable IGF-II, equivalent quantities of total IGF-II
from each sample (1.2 
 
m
 
g) were incubated with IGFBP-4–conjugated Af-
figel overnight at 4
 
8
 
C with gentle rocking. Samples were centrifuged for 10
min at 1,000 
 
g
 
 and the pellets washed three times with TBS. The pellets
were then incubated with 0.5 M acetic acid for 5 min to elute IGF-II
bound to the immobilized IGFBP-4. Supernatants were collected and
dried under vacuum. Samples were resuspended in TBS and the relative
levels of dissociable IGF-II determined using the IGF-II dot blot assay.
To validate that increasing the molar ratio of IGFBP-3 to IGF-II affects
IGF-II binding to the IGFBP-4 Affigel affinity media, increasing amounts
of recombinant IGFBP-3 were mixed with a constant amount of recombi-
nant IGF-II and the mixtures were subjected to the IGFBP-4 chromato-
graphic separation, as described above.
 
Receptor Kinase Assays
 
Frozen liver tissue samples were homogenized in TBS containing 1% Tri-
ton X-100, 1 mM PMSF, 100 
 
m
 
M Na
 
3
 
VO
 
4
 
, 1 mM EDTA, 10 
 
m
 
g/ml pepsta-
tin, 10 
 
m
 
g/ml leupeptin. Aliquots from each supernatant containing 5.0 
 
m
 
g
of protein were immunoprecipitated as above, using antibodies against the
IGF-IR (clone aIR3; Calbiochem). Immunoprecipitates were then incu-
bated with kinase reaction buffer (10 mM Hepes, pH 7.4, 5 mM MnCl
 
2
 
, 5 mM
MgCl
 
2
 
, 100 
 
m
 
M Na
 
3
 
VO
 
4
 
, 50 mM NaF) containing 2.0 
 
m
 
Ci/
 
m
 
l [
 
g
 
-
 
32
 
P]ATP ei-
ther with or without 50 
 
m
 
g Poly (Glu, Tyr) 4:1 (Sigma Chemical Co.) for
30 min at 37
 
8
 
C. Samples were electrophoresed on 10% SDS-PAGE gels,
dried onto Whatman 3 MM paper, and autoradiographed.
 
Phosphorylation Levels
 
Liver proteins were isolated as for the receptor kinase assays. For insulin
receptor substrate (IRS)-1, 2.5 mg of protein from each sample was im-
munoprecipitated with polyclonal antibodies against rat IRS-1 (Upstate
Biotechnology) as described above. The immunoprecipitates were then
Western blotted and the membranes probed sequentially with antiphos-
photyrosine (clone 4G10; Upstate Biotechnology) and anti–IRS-1 antibod-
ies. For mitogen-activated protein kinase (MAPK), replicate 10% SDS-
PAGE gels were run with 40 
 
m
 
g of protein from each sample loaded on
each gel. Following electroblotting, membranes were probed with anti-
bodies specific for phospho-MAPK or MAPK (New England Biolabs).
 
Densitometry and Quantification
 
Autoradiographs were scanned using a Molecular Dynamics Densitome-
ter. Absorbance was quantified using ImageQuant
 
®
 
 software. Statistical
significance was determined using 
 
t 
 
test. For all gel electrophoresis, each
lane corresponds to a tissue sample taken from an individual mouse. All
samples were obtained from 185-d-old female mice unless indicated other-
wise, as we determined previously that TIMP-1 modulation significantly
affected TAg-induced preneoplastic proliferation at this age (Martin et al.,
1999).
 
Results
 
TAg Antigen Molecular Interactions Are Maintained in 
TIMP-1–overexpressing Mice
 
We have shown previously that transgenic TIMP-1 expres-
sion does not affect TAg oncoprotein levels in double
transgenic mice that coexpress TAg and TIMP-1 trans-
genes (TAg
 
1
 
/Ts
 
1
 
) (Martin et al., 1996). Equivalent TAg
protein levels in both TAg
 
1
 
 and TAg
 
1
 
/Ts
 
1
 
 animals are
confirmed here in Fig. 1 a (top panel). Since TAg binds to
and inactivates the tumor suppressor gene products p53
and Rb to induce hyperplasia (Tan et al., 1986; DeCap-
rio et al., 1988), we investigated whether TAg interac-
tions with these tumor suppressor proteins are altered by
TIMP-1 overexpression. The amount of p53 and Rb that
coimmunoprecipitated with TAg protein was examined by
Western blotting and was found to be similar between
TAg
 
1
 
 and TIMP-1–overexpressing (TAg
 
1
 
/Ts
 
1
 
) livers, as
shown in Fig. 1 a (middle and bottom panels). This indi-
cates that TAg interactions with p53 and Rb proteins are
intact, and unaffected by the elevation of TIMP-1.
 
Cellular Proliferation Is Inhibited by Transgenic
TIMP-1 Despite IGF-II Reactivation
 
IGF-II is a fetal mitogen in rodents, and its transcription is
normally repressed in adult tissues by p53 (Zhang et al.,
1996). However, focal reactivation of IGF-II and its local-
ization to proliferating cells during TAg-induced tumori-
genesis have been reported in two independent transgenic
tumor models (Schirmacher et al., 1992; Christofori et al.,
1994). Cellular proliferation and tumor development have
been shown to be profoundly inhibited in one such model
when crossed onto an IGF-II–null background (Christo-
fori et al., 1994), revealing the fundamental importance of
IGF-II reactivation in TAg-induced tumorigenesis. IGF-II
reactivation has been frequently observed during TAg-
induced hepatocarcinogenesis (Casola et al., 1995; Had-
dad and Held, 1997). To investigate whether IGF-II was
reactivated in our hepatocellular carcinoma model, we ex-
amined its spatiotemporal expression in the livers of ex-
perimental and control littermates. IGF-II mRNA was not
detected by Northern blot analysis of liver tissue from
wild-type mice of all ages, or in the livers of TAg
 
1
 
 mice
before 165 d of age. However, from 170 d of age, multiple
IGF-II transcripts commonly observed in mouse and hu-
man tissues (Daughaday and Rotwein, 1989; Casola et al.,
1995) were expressed (Fig. 1 b, and data not shown). Fig. 1 c 
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shows that IGF-II mRNA was expressed in liver tissue
from TAg
 
1
 
 and TAg
 
1
 
/Ts
 
1
 
 littermates at 185 d of age.
Densitometric analysis of the major IGF-II transcript (4.2 kb)
confirmed that expression was comparable in TAg
 
1
 
 and
TAg
 
1
 
/Ts
 
1
 
 littermates (3.3 
 
6 
 
1.2 vs. 3.8 
 
6 
 
0.6,
 
 n 
 
5 
 
5 per
group). The timing of IGF-II reactivation coincided with
TAg-induced liver enlargement, and remained unaffected
by TIMP-1 overexpression. In contrast to IGF-II mRNA
reactivation, IGF-I mRNA expression remained very low
and unchanged during all stages of TAg tumorigenesis
(data not shown).
The liver-specific C reactive protein promoter, which di-
rects TAg expression (Rüther et al., 1993), resulted in uni-
form TAg expression in almost all hepatocytes by 185 d of
age, as shown by immunohistochemistry (Fig. 2 a). In adja-
cent sections, in situ hybridization revealed IGF-II mRNA
production by most hepatocytes (Fig. 2 b), and exten-
sive hepatocytic hyperplasia was detected by PCNA im-
munostaining (Fig. 2 c). The liver of a 185-d-old double
transgenic TIMP-1–overexpressing (TAg
 
1
 
/Ts
 
1
 
) littermate
demonstrated the same ubiquitous expression patterns of
both the TAg oncoprotein (Fig. 2 d) and IGF-II mRNA
(Fig. 2 e). In contrast, probing the adjacent sections with
anti-PCNA antibody revealed far less proliferation in the
livers of TAg
 
1
 
/Ts
 
1
 
 mice (Fig. 2 f) compared with TAg
 
1
 
mice. In our previous study using morphometric analysis,
we found this proliferation to be significantly suppressed
in TIMP-1 transgenic liver tissue (Martin et al., 1999). To-
gether, the results demonstrate that the effects of TIMP-1
are exerted downstream of IGF-II reactivation, but before
cell proliferation.
For further analyses of the effects of TIMP-1 on IGF-II
bioactivity, we chose to use liver specimens from 185-d-old
mice. This choice was based on our previous pilot study
encompassing 20–250 d, in which we found that hepato-
cyte proliferation was maximal (
 
.
 
65%) in TAg
 
1
 
 mice at
185 d of age, and was inhibited 3.3-fold in TAg
 
1
 
/Ts
 
1
 
 litter-
mates at this age (Martin et al., 1999). The difference in
proliferation was most accentuated at this age, and there-
fore we anticipated that in vivo analysis of molecular fac-
tors in the IGF-II signaling pathway would be most clearly
resolved at this point in time. The above observations that
IGF-II is reactivated in both TAg
 
1
 
 and TAg
 
1
 
/Ts
 
1
 
 livers
(Fig. 1 b and Fig. 2, b and e), yet hepatocyte proliferation
is only prevalent in TAg
 
1
 
 tissue at 185 d (Fig. 2, c and f),
further supported the use of this age group for IGF-II bio-
activity studies.
 
IGFBP-3 Levels Are Elevated Due to
Reduced Proteolysis
 
IGFPBs regulate IGF activity by sequestering free IGFs,
thus preventing ligand–receptor interactions. Previous
studies from one of our laboratories have demonstrated
that MMPs, the primary proteinases inhibited by TIMP-1,
can degrade IGFBPs both in vitro and in vivo (Fowlkes et al.,
1994a,b; Thrailkill et al., 1995; Fowlkes, 1997). Since the
amount of high-affinity, intact IGFBP may be regulated in
part by MMP-mediated proteolysis, we compared the lev-
els of intact hepatic IGFBPs using 
 
125
 
I–IGF-II Western
ligand blotting. Of the hepatic IGFBPs that bound 
 
125
 
I–
IGF-II on ligand blots, only IGFBP-3 (42–46-kD doublet)
levels were strongly affected by TIMP-1 modulation (Fig.
3 a). The levels of this binding protein, which is also the
major serum carrier protein for IGFs (Jones and Clem-
mons, 1995), were increased by more than twofold in the
livers of TIMP-1–overexpressing mice (TAg
 
1
 
/Ts
 
1
 
) com-
pared with levels in TAg
 
1
 
 littermates (Fig. 3 d, left panel;
 
P 
 
, 
 
0.02). TIMP-1 overexpression did not affect the levels
of IGFBP-4 (24–26 kD), although there were notable mi-
nor elevations of a doublet of proteins at 28–32 kD that,
based on molecular mass, likely represent IGFBP-1, -2,
and/or -5 (Fig. 3 a).
In contrast to IGFBP-3 protein levels, Northern blot
analysis showed that TIMP-1 overexpression did not affect
the levels of IGFBP-3 mRNA (Fig. 3 b), attributing the
differences in IGFBP-3 protein levels to posttranscrip-
tional events. MMP-1, -2, -3, and -9 have been shown to
proteolytically cleave IGFBP-2, -3, and -5, a process inhib-
ited by TIMP-1 in vitro (Fowlkes et al., 1994a,b; Thrailkill
et al., 1995; Fowlkes, 1997). Here, IGFBP-3 substrate zy-
mography (Fowlkes et al., 1997) was used to identify
Figure 1. Reactivation of IGF-II in TAg1 and TAg1/Ts1 livers.
(a) Western blots showed equivalent TAg levels in anti-TAg im-
munoprecipitates from the livers of 185-d-old TAg1 and TAg1/Ts1
littermates. Sequential probing of the blot showed that the levels
of p53 and pRB that coimmunoprecipitated with TAg were simi-
lar in TAg1 and TAg1/Ts1 livers. (b) Northern blot analysis of
IGF-II mRNA levels in the livers of TAg1 and TAg1/Ts1 trans-
genic littermates. IGF-II mRNA was undetectable in livers of
non-TAg expressing littermates, but was reactivated between 153
and 191 d of age in TAg-expressing littermates. (c) IGF-II mRNA
levels were the same in 185-d-old TAg1 and TAg1/Ts1 litter-
mates. RNA was isolated from livers from mice of the indicated
age and genotype (wt, wild-type; Ts1, TIMP-1 sense transgene–
expressing; Ta1, TIMP-1 antisense transgene–expressing; TAg1,
TAg transgene–expressing; TAg1/Ts1, double transgenic TIMP-
1–overexpressing). 18S ribosomal RNA and GAPDH provided a
means of determining RNA loading on the Northern blots. 
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IGFBP-3–degrading proteases in liver homogenates. We
found two IGFBP-3–degrading activities with molecular
masses of 
 
z
 
62 and 
 
z
 
84 kD (Fig. 3 c). Both activities
were substantially reduced in the presence of recombi-
nant TIMP-1 (Fig. 3 c), demonstrating that the IGFBP-
3–degrading proteinases were MMPs. Next, we determined
whether a decreased proteolysis of IGFBP-3 is evident in
liver tissue obtained from TIMP-1–overexpressing mice.
Liver homogenates were analyzed for their ability to de-
grade 125I–IGFBP-3 into smaller molecular weight species,
as described in Materials and Methods. There was signifi-
cantly less degradation of 125I–IGFBP-3 by liver homog-
enates from TIMP-1–overexpressing (TAg1/Ts1) mice
compared with TAg1 littermates (Fig. 3 d, right panel; P ,
0.02). These data suggest that TAg can induce MMPs that
are capable of degrading IGFBP-3, and that coexpression
of TIMP-1 can reduce MMP activity, thereby inhibiting
IGFBP-3 degradation. Together, these actions allow for a
net increase in tissue IGFBP-3 protein levels.
Dissociable IGF-II Levels Are Reduced by
Transgenic TIMP-1
We determined whether the increased IGFBP-3 levels
in the TIMP-1–overexpressing liver tissue affected the
amount of dissociable IGF-II. Fig. 4 a shows that using a
dot blot procedure developed to quantify total IGF-II
(bound and unbound; De Leon and Asmerom, 1997), re-
combinant IGF-II can be measured linearly over a range
of concentrations (0.4–3.2 mg). Next, dissociable IGF-II
was measured by IGFBP-4–conjugated Affigel affinity
chromatography. Using recombinant IGF-II and recombi-
nant IGFBP-3 in different molar ratios, we were able to
confirm that increasing molar ratios of IGFBP-3 reduced
Figure 2. Reduced hepato-
cyte proliferation in TIMP-
1–overexpressing (TAg1/
Ts1) livers. The TAg onco-
protein, IGF-II mRNA, and
proliferating hepatocytes
were localized on adjacent
sections of liver from 185-
d-old TAg1 and TAg1/Ts1
littermates. (a and d) Immu-
nohistochemical localization
showed the same consistent,
intense expression of TAg
throughout the livers of both
TAg1 and TAg1/Ts1 mice.
(b and e) Reactivated IGF-II
expression also occurred
throughout the liver of both
TAg1 and TAg1/Ts1 ani-
mals, as seen by in situ hy-
bridization. Inset, sense–
IGF-II riboprobes. (c and f)
In contrast to the equivalent
TAg protein and IGFII
mRNA levels in TAg1 and
TAg1/Ts1 mice, the lower
level of PCNA immunostain-
ing in TAg1/Ts1 livers
showed that there were
fewer proliferating hepato-
cytes in TIMP-1–overex-
pressing mice. The arrow-
heads indicate specific signal
in each panel. Bar, 100 mm.The Journal of Cell Biology, Volume 146, 1999 886
the amount of IGF-II that bound to the Affigel (Fig. 4 b).
To measure difference in levels of dissociable IGF-II in
liver samples, we first quantified total IGF-II using the dot
blot assay. Aliquots containing equivalent amounts of to-
tal IGF-II were subjected to the affinity chromatography
procedure. TIMP-1 overexpression resulted in a sixfold
decrease in dissociable IGF-II levels in the livers of TAg1/
Ts1 mice compared with their control TAg1 littermates
(Fig. 4 c; P , 0.02). This demonstrates that despite an
equivalent extent of IGF-II reactivation, the level of disso-
ciable or bioavailable IGF-II is reduced in TIMP-1–over-
expressing animals.
Reduced Signaling through the IGF-IR
A reduction in the levels of dissociable or bioavailable
IGF-II should result in decreased signaling through the
IGF-IR pathway in the livers of TAg1/Ts1 mice. Unlike
postnatal IGF-II inactivation that occurs in normal rodent
liver, the IGF-IR is expressed at constitutive levels in adult
Figure 3. Increased protein levels of IGFBP-3 and reduced
IGFBP-3 degradation in the livers of TIMP-1–overexpressing
(TAg1/Ts1) mice. (a) Ligand blot showing an increase in hepatic
IGFBP-3 in TAg1/Ts1 compared with TAg1 mice. (b) Northern
analysis showed that hepatic IGFBP-3 mRNA levels were the
same in TAg1 and TAg1/Ts1 littermates. (c) IGFBP-3 substrate
zymography showed the presence of proteinases in liver homoge-
nates that were capable of degrading IGFBP-3 and identified
them as MMPs, possibly MMP-2 and MMP-9, since they were in-
hibited by recombinant TIMP-1. (d) Bar graphs of IGFBP-3 pro-
tein levels and IGFBP-3 degradation showed that a twofold re-
duction in IGFBP-3 degradation resulted in a twofold increase in
IGFBP-3 levels. The mean absorbance values for positive con-
trols were assigned a value of 1.0. Bars, SD. Asterisk indicates
statistical significance in a t test of P , 0.02.
Figure 4. Reduced dissociable IGF-II in the livers of TIMP-
1–overexpressing (TAg1/Ts1) mice. (a) Bar graph showing the
optical density of dot blotted samples containing known concen-
trations of recombinant IGF-II (rIGF-II). (b) Bar graph showing
the impact of increasing molar ratios of IGFBP-3 to IGF-II on
levels of dissociable IGF-II using IGFBP-4 Affigel chromatogra-
phy. (c) Bar graph showing the relative levels of dissociable IGF-II
in liver tissue extracts from TAg1 and TAg1/Ts1 mice. n, number
of mice. For all graphs, samples were dot blotted in triplicate.
Bars, SD.Martin et al. A Novel Mechanism for TIMP-1–mediated Tumor Suppression 887
mouse liver, and IGF-II exerts its mitogenic effect through
this receptor (Osborne et al., 1989; Rubin and Baserga,
1995). Therefore, IGF-IR kinase activity, as well as the
phosphorylation status of the downstream signaling effec-
tors, IRS-1 and MAPK, were assessed. IGF-IR immuno-
precipitated from TAg1/Ts1 liver tissue exhibited lower
autophosphorylation (data not shown) and showed re-
duced kinase activity on an exogenous substrate (Fig. 5 a),
compared with receptor from TAg1 controls. Moreover,
tyrosine phosphorylation of IRS-1, which binds to IGF-IR
following activation, was also reduced in TIMP-1–overex-
pressing livers (Fig. 5 b, top panel). Sequential probing of
the same blot with an antibody against nonphosphorylated
IRS-1 showed that IRS-1 protein levels were not altered in
TIMP-1–overexpressing animals (Fig. 5 b, bottom panel).
Phosphorylation of the downstream signaling molecules,
the MAPKs extracellular signal regulatory kinase (Erk)-1
and Erk-2, was also reduced in TIMP-1–overexpressing
liver tissue (Fig. 5 c, top panel), whereas the absolute lev-
els of these proteins were unaffected (Fig. 5 c, bottom
panel). These data provide direct evidence that the protein
levels of the IGF-IR downstream signaling mediators were
not altered, but that signaling from the IGF-IR was atten-
uated in TIMP-1–overexpressing transgenic tissue.
Discussion
Regulation of the IGF-II Pathway by TIMP-1
IGFs are critical growth factors involved in growth, trans-
formation, and tumorigenesis and act through the IGF-IR
(for reviews see Jones and Clemmons, 1995; Rubin and
Baserga, 1995, Werner and Le Roith, 1997). Studies have
shown that cells null for the IGF-IR do not display the
normal increase in proliferation in response to growth fac-
tors or serum as seen in normal cells, and that all phases of
the growth cycle are prolonged (for review see Resnicoff
and Baserga, 1998). Indeed, in several cell lines, abroga-
tion of the IGF-IR has resulted in enhanced apoptosis.
Furthermore, IGF-IR–null cells cannot be transformed by
TAg (Sell et al., 1993), activated Ha-ras, a combination of
both, or by the overexpression of other growth factor re-
ceptors. And finally, a number of studies have shown that
ablation of this receptor in tumor cell lines significantly
Figure 5. Reduced signaling through the IGF-IR
in TIMP-1–overexpressing (TAg1/Ts1) livers. (a)
Receptor kinase assay showed greatly decreased
kinase activity of IGF-IR immunoprecipitated
from TAg1/Ts1 compared with TAg1 liver. (b and
c) Downstream of the IGF-IR, IRS-1 and Erk-1
and -2 had greatly reduced levels of phosphoty-
rosine, but equivalent protein levels in double
transgenic TAg1/Ts1 livers compared with TAg1
littermates. Quantification of the phosphotyrosine
and specific protein signal intensities illustrate the
extent of decrease of IRS-1 and Erk-1/2 tyrosine
phosphorylation in TAg1/Ts1 livers. Asterisk indi-
cates statistical significance (P , 0.05).The Journal of Cell Biology, Volume 146, 1999 888
decreases their tumorigenic potential in vivo. Together,
these data demonstrate that interruption of the ligand–
receptor interaction between IGFs and the IGF-IR effec-
tively disrupts several aspects of the tumorigenic process.
In nature, under homeostatic circumstances, little or no
IGFs are present in the free or bioavailable form due to
their sequestration by one or more of the six known high-
affinity IGFBPs. Because IGFBPs demonstrate equal or
higher affinities for IGFs than does the IGF-IR, little or no
IGFs are normally available to interact with receptors. Re-
cent studies have begun to elucidate mechanisms by which
IGFs can be released from IGFBPs so they may interact
with cell-surface receptors and exert their mitogenic and
metabolic effects. These studies have demonstrated that
a primary phenomenon invoked to release IGFs from
IGFBPs is through decreasing the affinities of IGFBPs for
IGFs. The best-characterized mechanism involved in de-
creasing the affinities of IGFBPs is proteolytic degrada-
tion (for review see Fowlkes, 1997).
Proteolytic cleavage has been demonstrated for at least
five IGFBPs, IGFBP-2 to IGFBP-6, and occurs in several
physiologic as well as pathologic circumstances (Jones and
Clemmons, 1995; Fowlkes, 1997), yet little is known of the
identity of these IGFBP-degrading proteinases in vivo, or
the mechanisms that regulate the proteolytic cleavage. In
vitro, we and others have provided evidence that produc-
tion of proteinases, a common feature of transformed cells
(Alexander and Werb, 1989), can result in degradation of
IGFBP–IGF complexes, releasing IGFs to interact with
cell surface receptors, thereby triggering proliferation of
target cells. We have also shown recently that in vitro,
MMPs function as IGFBP-3– and IGFBP-5–degrading
proteinases (Fowlkes et al., 1994a,b; Thrailkill et al., 1995).
In addition to degrading IGFBPs, extensive data also sup-
port the role of MMPs in tumorigenesis, angiogenesis,
and metastasis (Alexander and Werb, 1989; Flaumenhaft
and Rifkin, 1991; Liotta et al., 1991; Werb, 1997). In the
current studies, we now demonstrate the importance of
MMP-mediated IGFBP degradation in neoplastic prolif-
eration in vivo, and a means of controlling this degrada-
tion.
We have used a double transgenic, TAg-based tumor
model to determine directly whether TIMP-1 inhibits IGF
bioactivity in vivo to suppress hepatocyte proliferation
that leads to tumorigenesis. We selected this model as it
provided important features: (a) IGFs are crucial mitogens
for TAg-induced transformation, proliferation, and tu-
morigenesis (Schirmacher et al., 1992; Sell et al., 1993;
Christofori et al., 1994; Casola et al., 1995; Haddad and
Held, 1997); and (b) transgenic TIMP-1 overexpression in
this model substantially inhibits TAg-induced prolifera-
tion and hepatocellular carcinoma (Martin et al., 1996,
1999), making it possible to measure in vivo differences in
molecular factors and IGF-IR signal transduction in trans-
genic tissue. A systematic analysis has now been under-
taken to explore connections that might exist between
TAg expression and IGF-II bioactivity on cell prolifera-
tion to define the molecular mechanisms behind TIMP-
1–mediated tumor suppression in vivo. The events ex-
plored herein and the results are summarized in Fig. 6, and
are discussed below.
First, an examination of p53 and Rb in these mice
showed that TIMP did not interfere with the molecular in-
teractions between TAg and these tumor suppressor pro-
teins. Next, we found that IGF-II expression was indeed
reactivated at the onset of cell proliferation, similar to the
Figure 6. The molecular
mechanism underlying TIMP-
1–mediated suppression of
hepatocarcinogenesis. The
schematic highlights the mo-
lecular events that were exam-
ined here to uncover the
mechanism of TIMP-1–medi-
ated inhibition of hepatocyte
proliferation. The primary
event in the pathway between
TAg-induced IGF-II reactiva-
tion and hepatocyte prolifera-
tion affected by TIMP-1 over-
expression was an increase in
IGFBP-3 levels, due to the in-
hibition of MMP-mediated
proteolysis of IGFBP-3 by
TIMP-1. The direct result of
increased IGFBP-3 levels was
decreased dissociable IGF-II
levels concomitant with de-
creased signaling through the
IGF-IR and decreased hepa-
tocyte proliferation.Martin et al. A Novel Mechanism for TIMP-1–mediated Tumor Suppression 889
model of TAg-induced pancreatic tumorigenesis (Christo-
fori et al., 1994), indicating a key mitogenic role for IGF-II
in our tumor model. IGF-II reactivation is frequent in
TAg-induced liver tumorigenesis (Casola et al., 1995; Had-
dad and Held, 1997), as well as in liver tumor formation
induced by oncogene or growth factors (Liu et al., 1997;
Harris et al., 1998). Furthermore, our data showing that
TIMP-1 significantly inhibited hepatocellular proliferation
despite IGF-II reactivation suggested that TIMP-1 might
directly act at a posttranscriptional level to modulate
IGF-II activity. Our investigations reveal the novel finding
that hepatic TIMP-1 overexpression specifically inhibits
IGFBP-3 proteolysis, leading to a significant elevation of
hepatic IGFBP-3 levels. We have determined that MMPs
induced during TAg tumorigenesis (Martin et al., 1999)
appear to function in degrading IGFBP-3. Furthermore,
we demonstrate that dissociable IGF-II levels are de-
creased in TIMP-1–overexpressing hepatic tissue. The
physiologic consequence of reducing dissociable IGF-II
levels (e.g., a reduction in IGF-II bioactivity) was con-
firmed by demonstrating a significantly reduced signal
transduction from the IGF-IR, as measured by reduced
IGF-IR kinase activity and tyrosine phosphorylation
levels of IRS-1 and MAPK. Thus, despite TAg-induced
reactivation of IGF-II in the liver, the transgenic TIMP-
1–mediated increase of IGFBP-3 levels blocks TAg-
induced hepatocyte proliferation by effectively reducing
bioavailable IGF-II levels. Together, our data provide di-
rect evidence that the inhibition of extracellular proteoly-
sis by TIMP-1 attenuates the bioactivity of the tumor-
inducing growth factor IGF-II.
Transgenic TIMP or MMP Modulation and Effects on 
Early Tumor Development
Based on previous studies in transgenic systems, a rela-
tionship has begun to emerge between TIMP/MMP ex-
pression within a tissue and the tissue’s susceptibility to
tumor development. We have demonstrated that overex-
pression of TIMP-1 in the liver inhibits hepatocellular car-
cinoma (Martin et al., 1996), and its elevation in the skin
compromises the ability of transplanted lymphoma cells to
grow as a primary tumor (Krüger et al., 1997), whereas a
reduction of TIMP-1 in these tissues augments tumor de-
velopment (Martin et al., 1996; Krüger et al., 1997). Con-
sistent with these observations, the overexpression of
MMP-3 (stromelysin-1) in mammary tissue leads to spon-
taneous mammary tumor development (Sympson et al.,
1995) and the transgenic expression of MMP-I (type I col-
lagenase) in skin augments carcinogenesis (D’Armiento et
al., 1995). In addition, the ablation of MMP-7 (matrilysin)
impairs colorectal tumor development in the min mouse
tumor model (Wilson et al., 1997). In many of these stud-
ies, ectopic TIMP or MMP expression results in altered
cellular proliferation. For example, hepatic TIMP-1 over-
expression inhibits hepatocyte hyperplasia (Martin et al.,
1999), MMP-3 overexpression leads to mammary epithe-
lial hyperplasia (Sympson et al., 1994; Witty et al., 1995),
and MMP-1 overexpression to epidermal hyperprolifera-
tion (D’Armiento et al., 1995). Despite the many reports
indicating that shifts in the extracellular proteolytic bal-
ance have a strong influence on early tumor development
and on cell proliferation within the afflicted organ, the mo-
lecular mechanisms for these effects have remained elu-
sive. Having previously excluded the effects of TIMP-1 on
hepatocyte apoptosis (Martin et al., 1999), our present in-
vestigation provides in vivo evidence of a link between the
inhibition of extracellular proteolysis, reduced growth fac-
tor bioavailability, and reduced cellular proliferation. We
have shown previously that this reduction in cellular pro-
liferation precedes suppressed tumor development in this
model (Martin et al., 1996).
MMP Substrates of Importance other than ECM
during Tumorigenesis
TIMPs have traditionally been considered regulators of
cell invasion and motility by virtue of their ability to in-
hibit MMP-mediated ECM degradation. Now it is recog-
nized that in addition to the effects on ECM structural
proteins, extracellular proteolysis has the potential to con-
trol the release of growth factors tethered to the ECM
(Dallas et al., 1995; Whitelock et al., 1996), the processing
of soluble growth factor binding proteins, i.e., IGFBPs
(Fowlkes, 1997), and the processing of cell surface mole-
cules such as membrane-bound TNF-a, the Notch recep-
tor in Drosophila (Blobel, 1997), and the FGF receptor 1
(Levi et al., 1996). Although these and other studies
(Kimura et al., 1998) support the overall concept that ex-
tracellular proteolysis can broadly influence cell prolifera-
tion, behavior, and fate, the observations were made in in
vitro systems. To our knowledge, our data are the first in
vivo evidence to substantiate the importance of pro-
teolytic degradation of a tethering or binding/carrier pro-
tein for a growth factor in the pathological development of
cancer, and of its regulation by the natural inhibitor,
TIMP-1. Our data demonstrate that the dynamics of IGF-II
bioactivity can be altered in vivo by proteolytic modula-
tion, and emphasize that factors other than ECM proteins
constitute important physiological targets of MMP-medi-
ated cleavage within the extracellular microenvironment.
Role of IGF-II in Tumorigenesis
and Hepatocarcinogenesis
The importance of IGFs in cellular transformation has
been demonstrated by findings that cells which do not ex-
press IGF-IR cannot be transformed by any of a number
of dominant oncogenes (for review see Werner and Le
Roith, 1997). Indeed, TAg was unable to transform IGF-
IR–null fibroblasts, despite the presence of various growth
factors present in serum (Sell et al., 1993). Thus, IGF-IR is
necessary for TAg-mediated transformation to take place.
Consistent with these findings, TAg expression has been
shown to reactivate IGF-II gene transcription in vivo.
IGF-II reactivation occurs in pancreatic beta cells trans-
genically expressing TAg (Christofori et al., 1994), and
here we show that IGF-II reactivation occurs in hepato-
cytes expressing TAg transgene coincident with the onset
of hepatocyte hyperplasia. Similar to our finding, other in-
vestigators have reported that TAg expression in the liver
tissue coincides with reactivation of IGF-II gene transcrip-
tion and this reactivation has been associated with neo-
plastic transformation (Casola et al., 1995; Haddad and
Held, 1997). Such reactivation of IGF-II has also been re-The Journal of Cell Biology, Volume 146, 1999 890
ported during c-myc– and TGF-a–induced hepatocellular
carcinomas in transgenic mice (Liu et al., 1997; Harris et al.,
1998). The consequence of IGF-II reactivation as it relates
to neoplastic transformation has only been addressed re-
cently in TAg models of pancreatic cancer and hepatocel-
lular carcinoma. In the former study, the investigators
bred TAg transgenics into an IGF-II–null background
(Christofori et al., 1994), whereas in the latter TAg trans-
genics were bred into an Igf2 (1/2) background (Haddad
and Held, 1997). In both instances, tumor size and inci-
dence were decreased, strongly suggesting a role for IGF-II
in the pathogenesis of these two tumor types. Further-
more, several transgenic lines overexpressing IGF-II dem-
onstrate that IGF-II is associated with tumor formation,
including mammary tumors, lymphomas, and hepatocellu-
lar carcinomas (Rogler et al., 1994; Bates et al., 1995; for
review see Wolf et al., 1998). Although these studies pro-
vide compelling support for IGF-II as a causal mitogen in
the tumorigenesis evidenced in the current animal model,
final resolution of this hypothesis must await studies ex-
amining our findings in models that are either null or up-
regulated for IGF-II. Such studies are currently being pur-
sued in our laboratories.
Significance of Regulated IGF Bioavailability in 
Clinical Medicine
Both IGF-I and IGF-II are widely implicated in promot-
ing several human cancers, including liver, prostate, and
breast cancer, and their expression correlates with poorer
prognosis (Osborne et al., 1989; Tennant et al., 1996;
Werner and LeRoith, 1996; Sohda et al., 1997; Chan et
al., 1998; Hankinson et al., 1998). Furthermore, in trans-
genic models, IGF-I and IGF-II are causally implicated in
tumorigenesis (Rogler et al., 1994; Bates et al., 1995; Had-
sell et al., 1996; for review see Wolf et al., 1998). These
studies point to IGF bioactivity as a target for cancer ther-
apeutics. Our results indicate that TIMP-1–like biomole-
cules or synthetic MMP inhibitors may be promising can-
didates for the therapeutic modulation of IGF dosage in
novel clinical strategies. Alternatively, strategies to alter
specific IGFBP levels or the production of proteinase-
resistant IGFBPs (Chernausek et al., 1995; Conover et al.,
1995; Imai et al., 1998; Rees et al., 1998) may prove to be
effective therapeutic interventions. A distinct feature of all
of these approaches will be to target the bioavailability
rather than the production of a growth factor.
The results presented here provide compelling evidence
for a novel mechanism by which endogenous TIMPs con-
tribute to the cellular microenvironment. We demonstrate
that the inhibition of extracellular proteolysis in vivo im-
pairs the activity of a specific growth factor responsible for
hyperplasia during TAg-induced tumorigenesis. Because
TIMPs are also capable of inhibiting invasion, metastasis,
and angiogenesis (Khokha et al., 1989; DeClerck et al.,
1992; Khokha, 1994; Anand-Apte et al., 1997; Krüger et al.,
1997, 1998; Wang et al., 1997; Martin et al., 1999), all of
which are promoted by IGF action (Bae et al., 1998; Dunn
et al., 1998), the combined outcome of TIMP-1 elevation
may be to suppress multiple stages of tumor development,
maintenance, and progression.
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